Company news
Traws Pharma, Inc. news in 2023
Traws Pharma, Inc.'s news releases, calls and decks from 2023, newest first.
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
December 11, 2023
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
November 6, 2023
Encouraging Rigosertib Data Presented at EADV as Late Breaker
October 11, 2023
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
September 5, 2023
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
August 2, 2023
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
June 13, 2023
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
May 24, 2023
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 14, 2023
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
May 11, 2023
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
May 3, 2023
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
April 18, 2023
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
March 22, 2023
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
March 15, 2023
Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference
March 6, 2023
Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
February 6, 2023